

Clinical & Economic Performance of 3M[™] Prevena[™] Therapy:

(preventes

Protecting against the consequences of risk in the operating room and beyond.

Finding

3M[™] Prevena[™] Therapy and PICO[™] Therapy are not the

Prevena Therapy is the only medical device proven to aid risk patients, as well as in the reduction of complication-re



Prevena Therapy adds benefits to clinicians


Post-surgical complications can be costly and complicated. Prevena Therapy supports clinical safety goals by **helping reduce the incidence of seroma and protecting against superficial SSIs** in Class I and II wounds in high risk patients.

Two meta-analyses of peer reviewed randomized controlled trials (17 RCTs) published between January 2010 and June 2018 were conducted to evaluate the incidence of SSIs for two incision management systems.¹

Finding

Supporting the goals of managing risk beyond the OR, patients utilizing Prevena Therapy show reduced likelihood of SSI versus patients utilizing the standard of care (SOC).

- Meta-analysis #1: Prevena Therapy vs conventional dressings (SOC)
- Meta-analysis #2: PICO[™] Therapy vs conventional dressings (SOC)



same.

in the reduction of superficial surgical site infections (SSIs) in highlated events such as seroma, that can ripple beyond the OR.

ľ	H					
			Ξ			
			_			

Prevena Therapy adds benefits to hospitals

Prevena Therapy supports your facility's quality metrics and safety goals as the **ONLY medical** device proven to aid in the reduction of seromas and superficial SSIs.

Additional data from the RCTs included in the original meta-analyses publication compared outcomes in kit usage and dressing changes of closed incision management systems, Prevena Therapy and PICO[™] Therapy.²

Finding

Supporting the goals of lower touch care, fewer dressing kits and dressing changes were required with Prevena Therapy than PICO[™] Therapy.

	3M [™] Prevena [™] Therapy	PICO [™] Therapy
# of patients	489	532
required kits per patient	1	1.5 average
additional dressing changes per patient required	0	1.7 average

What this means: Clinical time and money may be saved when selecting Prevena Therapy, as facilities may ultimately pay more to treat patients with multiple PICO[™] Therapy kits and the increased volume of dressing changes.



The FDA granted the following Indications for Use:*

3M[™] Prevena[™] 125 and 3M[™] Prevena Plus[™] 125 Therapy Units manage the environment of closed surgical incisions and remove fluid away from the surgical incision via the application of -125mmHg continuous negative pressure. When used with legally marketed compatible dressings, Prevena 125 and Prevena Plus 125 Therapy Units are intended to aid in reducing the incidence of seroma and, in patients at high risk for post-operative infections, aid in reducing the incidence of superficial surgical site infection in Class I and Class II wounds.

For more information on the 3M[™] Prevena[™] Therapy System, contact your local representative.

References:

1. Singh D, Gabriel A, Silverman R, et al. Meta-analysis to compare outcomes of two different negative pressure therapy systems in closed incision management. *Plast Reconstr Surg Glob Open*. 2019;7:e2259.

2. Griffin L. Systematic review of dressing usage and cost analysis for two closed incision negative pressure therapy systems. 2019; HEOR-2019-001.DAR



3M Company 2510 Conway Ave St. Paul, MN 55144 USA

Phone 1-800-275-4524 (NPWT products) 1-800-228-3957 Web 3M.com/medical *The effectiveness of 3M[™] Prevena[™] Therapy in reducing the incidence of SSIs and seroma in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at **Prevena.com**

NOTE: Specific indications, limitations, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. Rx only.

© 2021 3M. All rights reserved. 3M and the other marks shown are marks and/or registered marks. Unauthorized use prohibited. 70-2011-8236-0 PRA-PM-US-02341 (04/21)